A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: * Adults 18 years≤ age ≤ 75 years, irrespective of gender, ethnicity, financial, and educational background. * Signed Informed Consent Form (ICF) prior to screening. * Participants with histologically or cytologically confirmed advanced solid tumors, who have failed standard treatment, or have no standard treatment, or intolerant to or not suitable for standard treatment. * Participants must have measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Predicted life expectancy of at least 3 months. * Adequate bone marrow reserve and organ function within 7 days prior to first dose of H1710. Exclusion Criteria: * Presence of malignant tumor lesion(s) that is/are at high risk of bleeding as judged by the clinical study investigator. * Active clinically significant bleeding or conditions with a high risk of hemorrhage. * Major surgery or in